Home › Funds › Prosight Management, LP › MLYS
Prosight Management, LP position in MLYS
MINERALYS THERAPEUTICS INC · Health Care
Prosight Management, LP reported holding 800,000 shares of MLYS (MINERALYS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$20.1M, representing 3.90% of its reported portfolio and ranking #11 among its reported holdings. Prosight Management, LP has disclosed MLYS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Prosight Management, LP's MLYS position evolved
Prosight Management, LP first disclosed a stake in MLYS in Q2 2026 at 449,795 shares (US$12.1M). The position peaked in Q3 2026 at 800,000 shares, worth US$20.1M. Across 2 filings, Prosight Management, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 800,000 shares valued at US$20.1M — an increase of 350,205 shares quarter over quarter.. Notable position changes include a 78% increase in Q3 2026 (shares fell 39% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 449.80K | $12.14M | New |
| Q3 2026 | 800.00K | $20.10M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLYS and 13F data
MLYS (MINERALYS THERAPEUTICS INC) is a Health Care company. 50 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLYS
- RA CAPITAL MANAGEMENT, L.P. 7.69M sh · $207.55M · Q2 2026
- Catalys Pacific, LLC 7.80M sh · $196.00M · Q3 2026
- Samsara BioCapital, LLC 5.87M sh · $158.40M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M sh · $106.79M · Q2 2026
- Laurion Capital Management LP 2.48M sh · $62.37M · Q3 2026
- ORBIMED ADVISORS LLC 2.11M sh · $56.94M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 1.56M sh · $42.20M · Q2 2026
- Andera Partners 1.59M sh · $40.00M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.47M sh · $39.66M · Q2 2026
- Ghisallo Capital Management LLC 1.12M sh · $30.35M · Q2 2026
- Logos Global Management LP 1.05M sh · $28.33M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.04M sh · $28.06M · Q2 2026
More on Prosight Management, LP
FAQ
How long has Prosight Management, LP held MLYS?
Prosight Management, LP has disclosed MLYS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Prosight Management, LP's current position in MLYS?
As of Q3 2026, Prosight Management, LP holds 800.00K shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $20.10M, representing 3.90% of its reported portfolio and ranking #11.
Has Prosight Management, LP been buying or selling MLYS?
In the latest 13F filing (Q3 2026), Prosight Management, LP increased its position in MLYS. The position peaked in Q3 2026 at 800.00K shares.
Which other funds hold MLYS?
Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.